What podcasts say about Abbott
Every statement, with the speaker, the exact quote and the moment it was said.
What experts have said about Abbott
10 statements · 5 positive · 5 negative
Abbott’s nutrition segment is the weak part of its portfolio
“they're finally spinning off their nutrition segment because that's probably the black sheep of the overall portfolio for them”
Open the episode · SpaceX, Tesla Boards Study Possible $3.5 Trillion MergerListen at 10:09
Spinning off nutrition allows Abbott to focus on medical devices
“that allows them to focus on their kind of key growth drivers, which is in the medical device space”
Open the episode · SpaceX, Tesla Boards Study Possible $3.5 Trillion MergerListen at 10:18
ACA or Medicaid cuts could reduce Abbott procedure volumes and revenue
“ACA cuts, Medicaid cuts, that could hurt some of their procedure volumes, which then would hurt revenue”
Open the episode · SpaceX, Tesla Boards Study Possible $3.5 Trillion MergerListen at 13:09
ACA or Medicaid cuts could reduce Abbott procedure volumes and revenue.
“that could hurt some of their procedure volumes, which then would hurt revenue”
Open the episode · SpaceX, Tesla Boards Study Possible $3.5 Trillion MergerListen at 13:12
New Abbott products can offset pricing cuts on legacy products
“get their product pipeline, get new products out there to launch, because that helps offset pricing cuts for their legacy products”
Open the episode · SpaceX, Tesla Boards Study Possible $3.5 Trillion MergerListen at 13:44
Abbott Labs was genuinely overvalued a year earlier.
“the overvaluation of an Abbott Labs a year ago was the real conundrum”
Open the episode · Mad Money w/ Jim Cramer 6/1/26Listen at 43:24
Abbott Labs missed its latest quarter and fell 34% year-to-date.
“Abbott missed its last quarter by a smidge and is now down 34% for the year.”
Open the episode · Mad Money w/ Jim Cramer 5/11/26Listen at 1:43
Abbott stock is a good buying opportunity after acquiring Exact Sciences
“I think that's crazy. Abbott has a big hold in its diagnostic business, and exact sciences would plug it. The rest of the business is doing quite well, so I think it's a terrific time to do some buying”
Open the episode · Mad Money w/ Jim Cramer 11/20/25Listen at 27:32
Investors should buy Abbott after its acquisition announcement.
“I think it's a terrific time to do some buying”
Open the episode · Mad Money w/ Jim Cramer 11/20/25Listen at 27:39
Investors should buy Abbott because Exact Sciences can accelerate growth.
“I think it's a terrific time to do some buying, especially as once in the portfolio, it will accelerate Abbott's growth rate.”
Open the episode · Mad Money w/ Jim Cramer 11/20/25Listen at 27:39
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.